Major players in the testosterone replacement therapy market are AbbVie Inc., Acerus Pharmaceuticals Corporation, Antares Pharma Inc., Bayer AG, BioTE.
Effectiveness of GRACE risk score in patients admitted to hospital with non-ST elevation acute coronary syndrome (UKGRIS): parallel group cluster randomised controlled trial bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.
Adding enzalutamide to ADT cuts risk for metastasis by 58% in prostate cancer subgroup healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
The addition of enzalutamide to androgen deprivation therapy extended metastasis-free survival among men with nonmetastatic, hormone-sensitive prostate cancer with high-risk biochemical recurrence, according to study results.The findings of the randomized, phase 3 EMBARK study, presented during American Urological Association Annual Meeting, also showed a statistically significant and clinically
Global hormone replacement therapy market demand is anticipated to reach 7.1% year on year to US$ 12 billion in 2032.Hormone replacement therapy (HRT) is predominantly used to relieve post-menopause symptoms. HRT replaces hormones that are low in levels as women approach menopause.During menopause, several women exp.